Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...
News-Medical.Net on MSN
Study tests combined targeted radiopharmaceuticals and precision radiation for recurrent prostate cancer
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...
On 16 January 2026, Telix Pharmaceuticals announced that the first U.S. patient had been dosed in BiPASS, a Phase 3 trial ...
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...
The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic and Therapeutic programs Dr. Alan ...
Prostate cancer is the most common cancer among men, yet it remains one of the least known. Prostate carcinoma affects about ...
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback